IOR-160

IOR-160 is a dual inhibitor of casein kinase 2 (CK2) and HDACs. IOR-160 exhibits high selectivity for CK2 (IC50 = 1.7 nM) and broad inhibitory activity against HDAC (HDAC 1, 2, 3, and 6 with IC50s of 3.3 nM, 24.0 nM, 3.9 nM, and 13.0 nM, respectively, with low activity for HDAC8) . IOR-160 modulates key cellular signaling pathways by inhibiting AKT phosphorylation and increasing acetylated α-tubulin. IOR-160 inhibits tumor growth and reduces tumor burden through dual CK2/HDAC inhibition. IOR-160 is indicated for use in triple-negative breast cancer research[1].

Product Specifications

CAS Number

[2421119-78-8]

UNSPSC

12352005

Target

Casein Kinase; HDAC

Related Pathways

Cell Cycle/DNA Damage; Epigenetics; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Smiles

O=C(NO)CCCCCCCNC1=NC2=C(C=CC(C(O)=O)=C2)C3=CN=CC=C31.O=C(O)C(F)(F)F

Molecular Formula

C23H25F3N4O6

Molecular Weight

510.46

References & Citations

[1]Ortín I, et al. Targeting Casein Kinase 2 and Histone Deacetylase with a Dual Inhibitor Effectively Reduces Tumor Growth in a Triple-Negative Breast Cancer Xenograft Model. ACS Pharmacol Transl Sci. 2025 Jul 1;8 (7) :2093-2105.